← All trials
NCT06170723
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 12, 2024
- Primary completion
- Mar 25, 2024
- Completion date
- Mar 25, 2024
- First posted
- Dec 14, 2023
- Last posted
- Dec 14, 2023
- Enrollment
- 32
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CelgeneLead sponsor
- Bristol-Myers SquibbOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.